Soc. Generale Knock-Out GNMSF/ DE000CL9G895 /
30/05/2024 09:22:51 | Chg.-0.24 | Bid22:00:36 | Ask22:00:36 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.15EUR | -10.04% | - Bid Size: - |
- Ask Size: - |
Genmab A/S | 1,777.2745 - | 31/12/2078 | Call |
GlobeNewswire
30/04
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03/04
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
17/10/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
25/09/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
04/09/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
19/10/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
20/09/2021
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
21/07/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021